MentiNova Inc. is developing an oral medication intended to reduce uncontrollable, often chaotic movements in Parkinson’s patients treated with L‑Dopa. The company is co‑founded by Dr. M. Maral Mouradian, the William Dow Lovett Professor of Neurology and Director of the Center for Neurodegenerative and Neuroimmunologic Diseases at the University of Medicine and Dentistry of New Jersey‑Robert Wood Johnson Medical School. Research to date has provided in‑vivo proof‑of‑principle data supporting the approach. MentiNova has raised $500,000 in funding from Foundation Venture Capital Group. The funds will be used to advance the status of its IND (Investigational New Drug) filing with the FDA and to perform clinical trials testing the efficacy of the treatment. The company is positioning the program toward clinical development to evaluate safety and efficacy in patients experiencing the uncontrollable movements associated with L‑Dopa treatment.

Total raised

$1M

Funding rounds

1

Latest round

Equity

Latest activity

Jan 2013